Massachusetts Republican Wants to Cap Potential MDMA Therapy Costs

Costs of the therapy are estimated at up to $15,000.

A Republican lawmaker in Massachusetts introduced a bill that would both reschedule the psychedelic MDMA at the state level and cap possible therapy costs at $5,000 per session, though both developments are contingent on federal rescheduling of the drug.

The bill – HD 2137, by state Rep. Nicholas Boldyga – was introduced in January, apparently in response to reporting by The Washington Post and The New York Times regarding moves by the nonprofit Multidisciplinary Association for Psychedelic Studies (MAPS), which estimated that the possible cost for MDMA treatments could reach as much as $13,000-$15,000 per patient, per visit.

Though it’s a nonprofit, MAPS has been lobbying for federal psychedelics reform, and the Times reported in 2021 that many stakeholders expect the U.S. Food and Drug Administration to approve MDMA for therapeutic use as soon as this year.

In preparation for that possibility, MAPS launched a new corporate entity in 2014, the MAPS Public Benefit Corporation.

“Winning FDA approval would give MAPS at least six years of exclusivity to market its MDMA-guided treatments for PTSD, with a potential windfall of $750 million,” The Times reported in 2021, without much added context.

The exclusivity agreement is why Boldyga’s bill was celebrated by some psychedelics activists in Massachusetts, who alleged to Psychedelic Spotlight that MAPS is “lobbying for an exclusive monopoly over MDMA therapy,” as Bay Staters for Natural Medicine founder James Davies put it.

MAPS director Dr. Rick Doblin, however, told The Times in 2021 that any money made from MDMA therapy would be used to fund new research into psychedelic therapy, train new doctors, and lobby for further reforms.

“Our goal is mass mental health,” Doblin told The Times. “It’s not to amass a whole bunch of money.”

In addition, the Washington Post made clear in 2020 that the potential cost that activists are worried about – up to $15,000 per therapeutic session – is due to how expensive the treatments themselves remain –  and because of obstacles getting such therapy covered by insurance.

That $15,000 price tag, The Post reported, included “42 hours of therapy, including three overnights,” as well as therapists working in “teams of two,” and found that clinicians are trying to bring costs down to make therapies more accessible for a wider patient base.

John Schroyer

John Schroyer has been a reporter since 2006, initially with a focus on politics, and covered the 2012 Colorado campaign to legalize marijuana. He has written about the cannabis industry specifically since 2014, after being on hand for the first-ever legal cannabis sales on New Year’s Day that year in Denver. John has covered subsequent marijuana market launches in California and Illinois, has written about every aspect of the marijuana trade, and was part of the team that built the cannabis industry’s first-ever trade show, MJBizCon. He joined Green Market Report in 2022.

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.

 Sign up

About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


Recent Tweets

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.